Last two presentations
Stockhouse doesn't let me paste the presentations! But it seems like about 15 employees have been laid off so far! As per previous announcements mostly R&D personal! The adjusted EBIDTA Q1, 2023 was minus $3.9M compared to first half of the 2023, minus $10M including the $4.4M of expenses related to oncology project. I really believe a bit more transparency regarding the financials and their plan of action going forward in order to meet the minimum liquidity requirement set by Marathon, approximate remaining costs for the restart, achieving positive EBIDTA etc. is really a must to do so all these talks about oncology costing 10s of millions or the company going bankrupt without any real numbers disclosed can end. Surely they should have factored in the cost savings and added costs due to oncology program among others before predicting the generation of adjusted positive EBIDTA by end of this calendar year.